Results 41 to 50 of about 4,431,933 (293)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Effect of stent placement on stone recurrence and post-procedural cholangitis after endoscopic removal of common bile duct stones [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims After endoscopic treatment of common bile duct (CBD) stones, recurrence of choledocholithiasis due to small stone fragments and post-endoscopic retrograde cholangiopancreatography (post-ERCP) cholangitis can occur.
Jung-Hye Choi, Tae-Yoon Lee, Young-Koog Cheon   +2 more
doaj   +1 more source

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives

The Turkish Journal of Gastroenterology, 2023
Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis.
Romelia Barba Bernal, Bryan Ferrigno, Esli Medina Morales, C. Castro, Daniela Goyes, Hirsh D. Trivedi, V. Patwardhan, A. Bonder   +7 more
semanticscholar   +1 more source

Bile Acids and Biliary Fibrosis

Cells, 2023
Biliary fibrosis is the driving pathological process in cholangiopathies such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou   +2 more
doaj   +1 more source

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Liver international (Print), 2023
Patients with primary biliary cholangitis (PBC) and insufficient response to ursodeoxycholic acid (UDCA), currently assessed after 1 year, are candidates for second‐line therapy.
C. Perez, S. Ioannou, Iman Hassanally, P. Trivedi, C. Corpechot, A. V. D. van der Meer, W. Lammers, P. Battezzati, K. Lindor, F. Nevens, K. Kowdley, T. Bruns, N. Cazzagon, A. Floreani, A. Mason, A. Gulamhusein, C. Ponsioen, M. Carbone, A. Lleo, M. Mayo, G. Dalekos, N. Gatselis, D. Thorburn, X. Verhelst, A. Parés, M. Londoño, H. Janssen, P. Invernizzi, R. Vuppalanchi, G. Hirschfield, B. Hansen, C. Levy   +31 more
semanticscholar   +1 more source

Chemokine receptor-5Delta32 mutation is no risk factor for ischemic-type biliary lesion in liver transplantation [PDF]

, 2009
It has been shown that certain chemokine receptor polymorphisms may correspond to certain complications after organ transplantation. Ischemic-type biliary lesion (ITBL) encounters for major morbidity and mortality in liver transplant recipients.
Christian Moench, Mönch, Christian, Peter Neuhaus, Christoph Heidenhain, Gero Puhl, Anja Lautem, Puhl, Gero, Neuhaus, Peter, Lautem, Anja, Heidenhain, Christoph   +9 more
core   +1 more source

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Alimentary Pharmacology and Therapeutics, 2023
Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects.
M. Mayo, J. Vierling, C. Bowlus, Cynthia Levy, G. Hirschfield, Guy W. Neff, M. Galambos, S. Gordon, Brian B. Borg, Stephen A. Harrison, P. Thuluvath, A. Goel, M. Shiffman, M. Swain, David Jones, P. Trivedi, A. Kremer, R. Aspinall, David A. Sheridan, Y. Dörffel, Ke Yang, Yun-Jung Choi, C. McWherter   +22 more
semanticscholar   +1 more source

Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. [PDF]

, 2010
TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), has been linked to inflammatory pathways as well as bile homeostasis, and could therefore be involved in primary sclerosing cholangitis (PSC) a chronic inflammatory bile duct disease. We aimed to
Bergquist Annika, Melum, E., Andreas Teufel, Franke Andre, Ellinghaus Eva, Michael P. Manns, Benedicte A Lie, Stokkers, Pieter C. F., Stokkers, P.C.F., Weismueller, Tobias, Manns, M., Beuers Ulrich, Mathew, C., Keitel, V., Schramm Christoph, Bergquist, A., Weersma, R., Vatn, M., Christian Rust, Vatn, Morten H, Christoph Schramm, Hov, Johannes R, Stiehl Adolf, Ponsioen, C., Teufel, A., Rust Christian, Ponsioen, Cyriel Y, Henckaerts, L., Schrumpf, E., Erik Schrumpf, Balschun, T., Haeussinger, Dieter, Lie, B., Franke, Andre, Pieter C F Stokkers, Espen Melum, Annika Bergquist, Mathew, Christopher G, Melum, Espen, Spomer Lina, Boberg, K., Häussinger, D., Jon K. Laerdahl, null null, Daniel Gotthardt, Onnie Clive M., Franke, A., Beuers, U., Eva Ellinghaus, Wijmenga, Cisca, IBSEN Study Group, Laerdahl, J.K., Vatn, Morten H., Cisca Wijmenga, Gotthardt Daniel, Weersma, Rinse K., Hov Johannes R., Stokkers Pieter C. F., Beuers, Ulrich, Keitel Verena, Boberg Kirsten M., ElSharawy, Abdou, Mathew, Christopher G.; id_orcid, Vatn Morten H., Johannes R. Hov, Lie, Benedicte A., Häussinger, Dieter, Hov, J.R., Runz Heiko, Schrumpf Erik, Onnie, C.M., Liesbet Henckaerts, Vermeire, S., Weismüller, T., Teufel Andreas, Bergquist, Annika, Dieter Häussinger, Mathew Christopher G., Karlsen, T.H., Karlsen Tom H., Lie, B.A., Morten H Vatn, Keitel, Verena, Spomer, Lina, Onnie, C., Mathew, Christopher G., Stokkers, Pieter C F, Morten H. Vatn, Manns, Michael P, Weersma, R.K., ElSharawy Abdou, Jon K Laerdahl, Vermeire, Severine, Schreiber Stefan, Christopher G Mathew, Melum Espen, Tobias Weismüller, Henckaerts Liesbet, Onnie, Clive M., Tom H Karlsen, Ponsioen, C.Y., Ellinghaus, Eva, Manke Thomas, Onnie, Clive M, Runz, H., Schreiber, Stefan, Cyriel Y Ponsioen, Kirsten M. Boberg, Laerdahl, Jon K, Stokkers, P., Wijmenga, C., Wijmenga Cisca, Schreiber, S., Lina Spomer, Abdou ElSharawy, Lie, Benedicte A, Weersma, Rinse K, Stiehl, A., Stefan Schreiber, Severine Vermeire, Kirsten M Boberg, Adolf Stiehl, Weersma, Rinse K.; id_orcid, Schrumpf, Erik, Boberg, K.M., Stiehl, Adolf, Heiko Runz, Weismüller Tobias, Schramm, C., Sterneck, Martina, Gotthardt, D., Rinse K. Weersma, Ellinghaus, E., Boberg, Kirsten M., Verena Keitel, Spomer, L., Wijmenga, Cisca; id_orcid, Manke, Thomas, Elsharawy, A., Cyriel Y. Ponsioen, Schramm, Christoph, Vermeire Severine, Tobias Balschun, Karlsen, Tom H, Laerdahl, Jon K., Rust, C., Karlsen, T., Runz, Heiko, Manns Michael P., Laerdahl, J., Clive M Onnie, Teufel, Andreas, Martina Sterneck, Lie Benedicte A., Sterneck Martina, Häussinger Dieter, Christopher G. Mathew, Laerdahl Jon K., Weersma Rinse K., Mathew, C.G., Weismüller, Tobias, Henckaerts, Liesbet, Ponsioen, Cyriel Y., Boberg, Kirsten M, Benedicte A. Lie, Andre Franke, Sterneck, M., Ulrich Beuers, Thomas Manke, Vatn, M.H., Johannes R Hov, Ponsioen Cyriel Y., Manke, T., Karlsen, Tom H., Rinse K Weersma, Balschun Tobias, Pieter C. F. Stokkers, Balschun, Tobias, Hov, Johannes R., Hov, J., Tom H. Karlsen, Manns, Michael P., Manns, M.P., Michael P Manns, Gotthardt, Daniel, Rust, Christian, Clive M. Onnie   +186 more
core   +4 more sources

Baricitinib and primary biliary cholangitis

Journal of Translational Autoimmunity, 2021
Background and aims: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA).
Stuart C. Gordon, Sheri Trudeau, Arie Regev, Jonathan M. Uhas, Sujatro Chakladar, Ana Pinto-Correia, Klaus Gottlieb, Doug Schlichting   +7 more
doaj   +1 more source

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

Journal of Hepatology, 2021
BACKGROUND AND AIM Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of disease progression.
J. Schattenberg, A. Parés, K. Kowdley, M. Heneghan, S. Caldwell, D. Pratt, A. Bonder, G. Hirschfield, C. Levy, J. Vierling, David E. J. Jones, A. Tailleux, B. Staels, S. Megnien, Rémy Hanf, D. Magrez, P. Birman, V. Luketic   +17 more
semanticscholar   +1 more source